Logo of Mayne Pharma (ASX:MYX)Latest Mayne Pharma (ASX:MYX) News

Page 1
Page 1 of 5

Mayne Pharma accepts A$604 million Richter takeover at 99.4% premium

Mayne Pharma has agreed to a A$6.40-a-share cash takeover by Hungary’s Gedeon Richter, valuing the company’s equity at approximately A$604 million. The recommended scheme still depends on regulatory clearances, shareholder and court approval, and completion of Mayne’s international business sale.
Victor Sage
17 Nov 2026

Market Wrap - Week 45 (2 Nov -> 6 Nov) 2026

NEXTDC, Vintage Energy and Embelton recorded the week’s biggest moves, but each came with a different reason and level of risk.
Across resources, takeovers and healthcare, investors rewarded firm deals while selling companies that still need cash or approvals.
Logan Eniac
7 Nov 2026

Healthcare Wrap - Week 45 (2 Nov -> 6 Nov) 2026

Healthcare shares delivered a mixed week as investors rewarded reimbursement and regulatory progress but punished cash calls and dilution. Noxopharm, Pacific Edge and Mayne Pharma led the largest moves, while several companies still face long waits before sales can grow.
Logan Eniac
7 Nov 2026

Mayne Pharma sells international arm for $55.5 million in US-focused reset

Mayne Pharma will sell its international operations, including the Salisbury manufacturing site, to Evaris Pharma for $55.5 million in cash. The deal leaves the company focused entirely on its US Women’s Health, Dermatology and DistributeRx businesses, subject to ACCC approval.
Victor Sage
6 Nov 2026

Healthcare Wrap - Week 44 (26 Oct -> 30 Oct) 2026

Healthcare shares split between clinical progress and cash pressure this week. Mesoblast rose on stronger Ryoncil sales, while several small biotechnology companies fell as investors weighed funding needs and delayed milestones.
Logan Eniac
31 Oct 2026

Mayne Pharma EBITDA halves as Women’s Health growth meets RHOFADE erosion

Mayne Pharma’s unaudited first-quarter revenue fell 2% to A$95.7 million, while underlying EBITDA dropped 52% as generic competition hit Dermatology. Strong prescription growth in Women’s Health and DistributeRx offered a partial counterweight, alongside progress on key legal disputes.
Victor Sage
26 Oct 2026

Healthcare Wrap - Week 42 (12 Oct -> 16 Oct) 2026

Healthcare shares swung between sharp selling and early commercial progress this week, with EBR Systems falling 40.43% while Firebrick rose 13.79%.
Sales growth, clinical decisions and limited cash reserves remained the key tests for small healthcare companies.
Logan Eniac
17 Oct 2026

Mayne Pharma clears final IMVEXXY patent dispute with Teva

Mayne Pharma has settled its final US Paragraph IV patent dispute over IMVEXXY with Teva, setting a potential generic entry date of 2 September 2032. The agreement removes ongoing litigation without an upfront payment, while leaving court approval and earlier-entry provisions to resolve.
Victor Sage
16 Oct 2026

Healthcare Wrap - Week 40 (28 Sept -> 2 Oct) 2026

Clinical setbacks and cash shortages weighed on healthcare shares, while selected companies advanced on sales, regulatory and patent news.
Investors now face a simple test: which businesses can turn their latest announcements into funded operations and revenue?
Logan Eniac
3 Oct 2026

Mayne Pharma Sets 2032 Generic Entry Date for IMVEXXY

Mayne Pharma has settled patent litigation with Sun Pharma over IMVEXXY, establishing 21 October 2032 as the agreed potential generic entry date, subject to court approval. The settlement involves no upfront payment, while one further Paragraph IV dispute remains unresolved.
Victor Sage
30 Sept 2026

Healthcare Wrap - Week 23 (1 June -> 5 June) 2026

Healthcare stocks split into two camps this week. Buyers chased clear commercial wins, while several halted names gave back early excitement once trading resumed. The biggest moves came from a collapse in Opthea, a surge in Control Bionics, and a strong jump in Biome Australia after a margin-boosting manufacturing deal.
Logan Eniac
6 June 2026

Mayne Pharma Secures $14.4M Legal Costs from Cosette After Court Ruling

Mayne Pharma has received $14.4 million from Cosette Pharmaceuticals covering legal costs and interest following a Supreme Court ruling in its favour. The legal battle continues with Cosette’s appeal decision pending.
Victor Sage
5 June 2026